Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$137.92 USD
+0.09 (0.07%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $137.86 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,887 | 1,489 | 1,134 | 1,046 | 788 |
Cost Of Goods | 40 | 23 | 14 | 10 | 7 |
Gross Profit | 1,847 | 1,466 | 1,119 | 1,036 | 781 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,597 | 1,217 | 1,017 | 873 | 708 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Non-Operating Income | 86 | -28 | 25 | -24 | 6 |
Interest Expense | 5 | 7 | 26 | 33 | 32 |
Pretax Income | 332 | 214 | 101 | 107 | 47 |
Income Taxes | 82 | 59 | 12 | -301 | 10 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 250 | 155 | 90 | 407 | 37 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 250 | 155 | 90 | 407 | 37 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 255 | 266 | 131 | 193 | 98 |
Depreciation & Amortization (Cash Flow) | 4 | 17 | 28 | 30 | 26 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 101.00 | 98.90 | 97.90 | 97.80 | 95.70 |
Diluted EPS Before Non-Recurring Items | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Diluted Net EPS (GAAP) | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 515.20 | 498.80 | 452.70 | 420.40 | 412.00 |
Cost Of Goods | 8.50 | 11.20 | 11.50 | 8.50 | 7.70 |
Gross Profit | 506.70 | 487.60 | 441.20 | 411.90 | 404.30 |
SG&A, R&D, and Dept/Amort Expenses | 356.40 | 346.40 | 367.60 | 526.10 | 300.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 150.30 | 141.20 | 73.60 | -114.20 | 103.40 |
Non-Operating Income | 49.00 | -24.50 | 49.30 | 12.00 | 15.60 |
Interest Expense | 1.10 | 1.10 | 1.30 | 1.10 | 1.10 |
Pretax Income | 198.20 | 115.60 | 121.60 | -103.30 | 117.90 |
Income Taxes | 50.50 | 32.50 | 26.10 | -26.70 | 28.90 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 147.70 | 83.10 | 95.50 | -76.60 | 89.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 147.70 | 83.10 | 95.50 | -76.60 | 89.00 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 102.30 | 101.10 | 100.20 | 97.10 | 100.80 |
Diluted EPS Before Non-Recurring Items | 1.44 | 0.82 | 0.95 | -0.79 | 0.88 |
Diluted Net EPS (GAAP) | 1.49 | 0.82 | 0.95 | -0.79 | 0.91 |